NASDAQ · Biotechnology

FTRE (FTRE) Stock

$18.43 +4.18% NASDAQ: FTRE Healthcare

Valuation

MetricValue
Price$18.43
Market Cap$1.75B
P/E Ratio-1.26
P/B Ratio2.29
P/S Ratio0.47
EPS (TTM)$-10.81
52-Week High$19.74
52-Week Low$4.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-174.82%
ROA-36.30%
ROCE-5.50%
Gross Margin-1.14%
Operating Margin-1.14%
Net Margin-16.50%
Debt/Equity0.14
Current Ratio0.98

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.1B$2.8B$2.8B$2.7B$2.7B
Operating Profit$114.0M$187.0M$32.0M$-162.0M$-31.0M
Net Profit$98.0M$186.0M$-25.0M$-328.0M$-986.0M
EPS$1.11$2.11$-0.04$-3.67$-10.81
Op Margin3.7%6.6%1.1%-6.0%-1.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$4.4B$4.3B$4.3B$3.6B$2.7B
Total Liabilities$1.1B$945.0M$2.6B$2.2B$2.2B
Cash$95.0M$112.0M$109.0M$119.0M$175.0M
Borrowings$77.0M$63.0M$1.7B$1.2B$68.0M

Latest News

FTRE: Raising target price to $19.00 Argus Research · Jul 15, 2026 BofA Adjusts Price Target on Fortrea Holdings to $11 From $9.50 MT Newswires · Jul 13, 2026 Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call GlobeNewswire · Jul 13, 2026 Fortrea (FTRE) Stock Still Screens Cheap After Its 248% Run Simply Wall St. · Jul 12, 2026 Is Fortrea Holdings (FTRE) Overvalued After Its Rally To $17.76? Simply Wall St. · Jul 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$170.0M$83.0M$168.0M$263.0M$114.0M
Investing Cash Flow$-53.0M$-108.0M$-72.0M$226.0M$-11.0M
Financing Cash Flow$-128.0M$-6.0M$-1.8B$-15.0M$0
Net Cash Flow$14.0M$16.0M$-2.0M$10.0M$56.0M
Free Cash Flow$143.0M$28.0M$128.0M$237.0M$88.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA25.21
FCF Yield14.81%
Quick Ratio0.95
Interest Coverage-0.34
Return 1Y206.66%
Return 3Y-42.73%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANAB $53.61 -1.00% -127.70 $2.31B 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
BBOT $8.09 -4.82% -3.62 $648.07M 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%

About FTRE

FTRE is led by CEO Anshul Thakral, employs 15,000 people, headquartered in US, publicly traded since 2023.

FTRE stock trades at $18.43 with a market capitalization of $1.75B. The stock is valued at a price-to-earnings (P/E) ratio of -1.26, price-to-book of 2.29, price-to-sales of 0.47. Over the past 52 weeks the stock has ranged between $4.36 and $19.74, and currently trades 6.6% below its 52-week high.

On profitability, FTRE generates a return on equity (ROE) of -174.82%, return on capital employed of -5.50%, an operating margin of -1.14%, a net profit margin of -16.50%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides